"European Medicines Agency Approves Pfizer's RSV Vaccine for Infants and Older Adults"
The European Medicines Agency (EMA) has recommended granting marketing authorization for Abrysvo, the first vaccine to protect against respiratory syncytial virus (RSV) in infants up to 6 months old and older adults. RSV is a common respiratory virus that can cause severe illness in children and older adults. Abrysvo is a bivalent vaccine that provides passive immunization to infants when administered to the mother during pregnancy and active immunization to adults aged 60 and older. The vaccine has shown efficacy in reducing RSV-associated illnesses in clinical trials. The opinion will now be sent to the European Commission for a decision on EU-wide marketing authorization.